Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations

NCT02138916 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02138916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02138916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 13, 2014
Completion date
April 10, 2018
Enrollment
1,656 (actual)
Sites
407

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to very severe chronic obstructive pulmonary disease